Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBT (2016 - 2025)

Collegium Pharmaceutical has reported EBT over the past 10 years, most recently at $29.0 million for Q4 2025.

  • Quarterly results put EBT at $29.0 million for Q4 2025, up 68.14% from a year ago — trailing twelve months through Dec 2025 was $92.6 million (down 6.04% YoY), and the annual figure for FY2025 was $92.6 million, down 6.04%.
  • EBT for Q4 2025 was $29.0 million at Collegium Pharmaceutical, down from $43.4 million in the prior quarter.
  • Over the last five years, EBT for COLL hit a ceiling of $46.7 million in Q4 2023 and a floor of -$38.9 million in Q4 2021.
  • Median EBT over the past 5 years was $15.5 million (2021), compared with a mean of $11.7 million.
  • Peak annual rise in EBT hit 3338.67% in 2021, while the deepest fall reached 635.33% in 2021.
  • Collegium Pharmaceutical's EBT stood at -$38.9 million in 2021, then soared by 79.96% to -$7.8 million in 2022, then skyrocketed by 699.54% to $46.7 million in 2023, then plummeted by 63.03% to $17.3 million in 2024, then surged by 68.14% to $29.0 million in 2025.
  • The last three reported values for EBT were $29.0 million (Q4 2025), $43.4 million (Q3 2025), and $17.0 million (Q2 2025) per Business Quant data.